Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Daly

Showing results (361-370 of 397) with videos related to

Pageof 40
Sort By:
Alcoholism, Clinical and Experimental Research|April 16, 2015
Brief report: genetics of alcoholic cirrhosis-GenomALC multinational studyJohn B Whitfield, Khairunnessa Rahman, Paul S Haber, et al.
JHEP Reports : Innovation in Hepatology|January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevanceKatherine Johnson, Peter J Leary, Olivier Govaere, et al.
Clinical Pharmacology and Therapeutics|January 21, 2019
Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen AllelesPaola Nicoletti, Guruprasad P Aithal, Thomas C Chamberlain, et al.
Gastroenterology|December 10, 2022
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-ClavulanatePaola Nicoletti, Andrew Dellinger, Yi Ju Li, et al.
American Journal of Epidemiology|July 16, 2002
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE reviewLawrence S Engel, Emanuela Taioli, Ruth Pfeiffer, et al.
Cancers|April 3, 2021
A <i>PDCD1</i> Role in the Genetic Predisposition to NAFLD-HCC?Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, et al.
Gastroenterology|January 22, 2019
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver InjuryElizabeth T Cirulli, Paola Nicoletti, Karen Abramson, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Pharmacogenetics and Genomics|September 13, 2012
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugsThomas J Urban, Yufeng Shen, Andrew Stolz, et al.
Pharmacogenomics|April 2, 2026
The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congressRon H N van Schaik, Jesse J Swen, Adrián Llerena, et al.
Pageof 40

Showing results (361-370 of 397) with videos related to

Sort By:
Pageof 40
Alcoholism, Clinical and Experimental Research|April 16, 2015
Brief report: genetics of alcoholic cirrhosis-GenomALC multinational studyJohn B Whitfield, Khairunnessa Rahman, Paul S Haber, et al.
JHEP Reports : Innovation in Hepatology|January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevanceKatherine Johnson, Peter J Leary, Olivier Govaere, et al.
Clinical Pharmacology and Therapeutics|January 21, 2019
Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen AllelesPaola Nicoletti, Guruprasad P Aithal, Thomas C Chamberlain, et al.
Gastroenterology|December 10, 2022
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-ClavulanatePaola Nicoletti, Andrew Dellinger, Yi Ju Li, et al.
American Journal of Epidemiology|July 16, 2002
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE reviewLawrence S Engel, Emanuela Taioli, Ruth Pfeiffer, et al.
Cancers|April 3, 2021
A <i>PDCD1</i> Role in the Genetic Predisposition to NAFLD-HCC?Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, et al.
Gastroenterology|January 22, 2019
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver InjuryElizabeth T Cirulli, Paola Nicoletti, Karen Abramson, et al.
Nature Communications|July 1, 2014
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver diseaseYang-Lin Liu, Helen L Reeves, Alastair D Burt, et al.
Pharmacogenetics and Genomics|September 13, 2012
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugsThomas J Urban, Yufeng Shen, Andrew Stolz, et al.
Pharmacogenomics|April 2, 2026
The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congressRon H N van Schaik, Jesse J Swen, Adrián Llerena, et al.
Pageof 40